Janney Cuts Price Target on Cara Therapeutics (CARA) as UP is Delayed
Tweet Send to a Friend
Janney Capital maintained a Buy rating on Cara Therapeutics (NASDAQ: CARA), and cut the price target to $18.00 (from $23.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
